CSPC Pharmaceutical Group (HKG:1093) said Friday that its Enlida injection for a rare autoimmune disease has been approved for use in China in combination with conventional drugs.
The company said the approval from the National Medical Products Administration followed positive results from a phase III study in China in subjects with generalized myasthenia gravis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments